Cargando…
Review of miglustat for clinical management in Gaucher disease type 1
Gaucher disease is a progressive lysosomal storage disorder caused by the deficiency of glucocerebrosidase, and characterized by intralysosomal storage of glucosylceramide that leads to dysfunction in multiple organ systems. Intravenous enzyme replacement with imiglucerase is the accepted standard f...
Autor principal: | Ficicioglu, Can |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504062/ https://www.ncbi.nlm.nih.gov/pubmed/18728838 |
Ejemplares similares
-
Eye Movement Impairment Recovery in a Gaucher Patient Treated with Miglustat
por: Accardo, Agostino, et al.
Publicado: (2010) -
Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series
por: Serratrice, Christine, et al.
Publicado: (2015) -
Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
por: Amato, Dominick, et al.
Publicado: (2018) -
Substrate reduction therapy with miglustat for type 1 Gaucher disease: A retrospective analysis from a single institution
por: Machaczka, Maciej, et al.
Publicado: (2012) -
Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report
por: Giuffrida, Gaetano, et al.
Publicado: (2016)